Maturity-onset diabetes of the young (MODY) is a genetically heterogeneous subtype of non-insulin-dependent diabetes mellitus (NIDDM
INTRODUCTION
Maturity-onset diabetes of the young (MODY) is a genetically heterogeneous subtype of non-insulin-dependent diabetes mellitus (NIDDM) characterised by early onset, usually before 25 years of age, autosomal dominant inheritance (1) and a primary defect in insulin secretion (2) (3) (4) (5) (6) . MODY occurs world-wide and we have estimated that 13% of Caucasian families collected in France have this form of diabetes (7) . Genetic studies have previously localised three MODY genes on chromosomes 20q (MODY1) (8) , 7p (glucokinase/MODY2) (9) and 12q (MODY3) (10) . MODY2 appears to be the most common form of MODY in France and so far 36 different glucokinase mutations have been described in 42 unrelated families (11) . Clinical studies have shown that mutations in glucokinase/MODY2 result in mild chronic hyperglycaemia due to reduced pancreatic beta cell responsiveness to glucose (2, 3) , and decreased net accumulation of hepatic glycogen and increased hepatic gluconeogenesis following meals (12) . In contrast, the clinical phenotypes of MODY1 and MODY3 are characterised by severe insulin secretory defects (4-6), and by major hyperglycaemia associated with microvascular complications (1, 13) .
Recently, Yamagata et al. (14) showed that MODY3 was the gene encoding the hepatocyte nuclear factor 1 alpha (HNF-1α, *To whom correspondence should be addressed symbol TCF1). This transcription factor is involved in tissue specific regulation of liver genes (15) , and is also expressed in pancreatic islets and other tissues. Seven different mutations in HNF-1α were found to co-segregate with NIDDM in seven MODY families (14) . MODY1 was identified as the gene encoding the hepatocyte nuclear factor 4 alpha (HNF-4α) (16), a member of the steroid/thyroid hormone receptor superfamily and upstream regulator of HNF-1α expression.
In this study, we have examined ten unrelated Caucasian families in which MODY/NIDDM co-segregated with markers for MODY3 (10) for mutations in the HNF-1α gene. We report the identification of ten different mutations which co-segregated with diabetes in these families.
RESULTS
The ten exons and flanking intronic regions of one affected member from each of ten MODY3-linked families (nine French and one Swiss) ( Fig. 1) were amplified using PCR and sequenced directly. Ten different mutations were identified in these families (Table 1) , each of which co-segregated with diabetes. Of these the P379fsdelCT mutation was previously reported in one British family (14) and the remainder are newly described. The five frameshift and two nonsense mutations are predicted to lead to the synthesis of a truncated protein. The three missense mutations, all of which are located in exon 2, are mutations of residues that are conserved in the sequences of human, rat, mouse, hamster, chicken, salmon and Xenopus HNF-1α, and the structurallyrelated HNF-1β implying that these residues are functionally important. In addition to showing that each mutation co-segregated with diabetes, we also screened 60 healthy unrelated non-diabetic French subjects (120 chromosomes) for each mutation and have not observed any in this group. As shown in Figure 1 , seven of 67 carriers of mutations have normal glucose tolerance at the present time. Six of these are less than 25 years of age and thus still at risk of developing diabetes in the future, and one carrying a missense mutation (Fig. 1, F515-20) is 42 years, suggesting he may indeed be non-penetrant. Thus, mutations in MODY3 are highly but not completely penetrant.
DISCUSSION
Mutations in HNF-1α result in a subtype of MODY characterised by a severe insulin secretory defect. However, little is known about the pathophysiological mechanisms leading to this secretory defect. They might include abnormal pancreatic islet development during foetal life thereby limiting their later function, as well as impaired transcriptional regulation of genes, the identities of which are presently unknown, that play a key role in normal pancreatic beta cell function.
Regarding the clinical profile of MODY3 subjects, one might expect that subjects with frameshift and nonsense mutations may be more severely affected than those with missense mutations. However, there were no apparent differences in the age at onset or severity of diabetes between these two groups of affected subjects (data not shown). More detailed clinical studies might reveal subtle differences between these groups as found in studies of patients with different types of mutations in the glucokinase gene (3). HNF-1α is composed of three functional domains: a NH 2 -terminal dimerisation domain, a DNA binding domain with POU-like and homeodomain-like motifs and a COOH-terminal transactivation domain (Fig. 2) (15) . The functional form of HNF-1α is a dimer, either a homodimer or a heterodimer with HNF-1β (17) . In liver and pancreas, homodimers are predominant compared to kidney where 50% of the molecules are HNF-1α/HNF-1β heterodimers. Thus, a heterozygous mutant may lead to a marked decrease of HNF-1α activity in pancreas and liver with a smaller effect in kidney (18) . However, the genetic mechanism whereby these heterozygous mutations lead to MODY is not clear; possible mechanisms include a gene dosage effect as in MODY2 (19) , or a dominant negative effect (20) . The identification of the Q7X mutation in a MODY family does not support a dominant negative mechanism, at least for this mutation, and is consistent with gene dosage as being the possible mechanism. This mutation results in the expression of a very short protein bearing only six out of the 31 amino acids of the dimerisation domain. It is unlikely that this mutant could bind effectively to the normal HNF-1α and HNF-1β molecules and exert a dominant negative effect. Interestingly, studies of HNF-1α deficient transgenic mice support a dominant negative mechanism (18) . Homozygous animals completely lacking HNF-1α suffer from phenylketonuria and renal tubular dysfunction with massive glycosuria (up to 10% of their body weight daily). They are mildly hyperglycaemic despite the massive glucosuria, suggesting that they might have an insulin secretory defect. The heterozygous mice seem to be phenotypically normal suggesting that a 50% reduction of HNF-1α, at least in mice, does not necessarily lead to diabetes and kidney abnormalities.
In conclusion, HNF-1α is a major gene for MODY with mutations in this transcription factor being present in 25-50% of French patients with MODY (10) . Its role in the susceptibility to the more common late-onset NIDDM is less certain. Linkage studies seem to exclude a role as a major susceptibility gene (21, 22) but leave unresolved whether it may have a small effect. Mahtani et al. recently proposed that mutations in MODY3 might be responsible for diabetes in a subgroup of subjects with late-onset NIDDM characterised by low insulin secretion (22) . If confirmed, HNF-1α would be the most common NIDDM susceptibility gene identified to date.
MATERIALS AND METHODS
One affected subject from each of the ten MODY3 families was screened for mutations in the HNF-1α gene, as described previously (14) by PCR amplification of each exon and direct sequencing of the PCR product. The sequence of each mutation was confirmed by cloning the PCR product into the vector pGEM TM -T (Promega, Madison, WI) and sequencing clones representing both alleles. The presence of the specific mutation within each family was assessed by amplifying and directly sequencing the appropriate exon for all the affected and unaffected family members.
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